Full Text
Abstract
Summary. Sepsis-induced coagulopathy (SIC) increases mortality in sepsis, with effective methods to address it not yet developed.
Аim: to substantiate the use of cryosupernatant plasma (CSP) as a means of addressing SIC. Hemostasis disorders in SIC are ambivalent. Manifestations of hypercoagulation include increased levels of factor (F) VIII, von Willebrand factor (vWF), and fibrinogen, as
well as decreased levels of antithrombin III, protein C, and ADAMTS‑13 metalloproteinase. Hypocoagulation due to consumption of
coagulation factors includes prolongation of activated partial thromboplastin time (aPTT), prothrombin time/international normalized
ratio (PT/INR), and viscoelastic disorders. As compared with fresh frozen plasma (FFP) сryosupernatant is depleted in FVIII, vWF, and
fibrinogen. The concentrations of vitamin K-dependent coagulation factors, antithrombin III, protein C and ADAMTS‑13 are the same
as in FFP and cryoprecipitate. Considering specific features of coagulation disorders in SIC, CSP may be effective for its management.
For citation: Bulanov A.Yu., Lyanguzov A.V. Cryosupernatant transfusion for sepsis-induced coagulopathy correction. Tromboz, gemostaz i reologiya.
2025;(3):21–26. (In Russ.).
Reference
1. Williams B., Zou L., Pittet J.F., ChaoW. Sepsis-induced coagulopathy: a comprehensive narrative review of pathophysiology, clinical
presentation, diagnosis, and management strategies. Anesth Analg.
2024;138(4):696–711. DOI: 10.1213/ANE.0000000000006888.
2. Singer M., Deutschman C.S., Seymour C.W. et al. The third International consensus definitions for sepsis and septic shock (Sepsis‑3). JAMA. 2016;315(8):801–10. DOI: 10.1001/jama.2016.0287.
3. Cecconi M., Evans L., LevyM., Rhodes A. Sepsis and septic shock.
Lancet. 2018;392(10141):75–87. DOI: 10.1016/S0140‑6736(18)30696‑2.
4. Levi M., van der Poll T. Coagulation and sepsis. Thromb Res.
2017;149:38–44. DOI: 10.1016/j.thromres.2016.11.007.
5. Lyanguzov A.V., Bulanov A.Yu., Ignatyev S.V. et al. Sepsis-induced
coagulopathy in blood cancer patients with infectious complications. Tromboz, gemostaz i reologiya. 2024;(4):20–8. (In Russ.).
DOI: 10.25555/THR.2024.4.1118.
6. Schmoch T., Möhnle P., Weigand M.A. et al.; SepNet–Critical Care
Trials Group. The prevalence of sepsis-induced coagulopathy in
patients with sepsis — a secondary analysis of two German multicenter randomized controlled trials. Ann Intensive Care. 2023;13(1):3. DOI: 10.1186/s13613‑022‑01093‑7.
7. Sungurlu S., Kuppy J., Balk R.A. Role of antithrombin III and tissue factor pathway in the pathogenesis of sepsis. Crit Care Clin.
2020;36(2):255–65. DOI: 10.1016/j.ccc.2019.12.002.
8. De Backer D., Orbegozo Cortes D., Donadello K., Vincent J.-L. Pathophysiology of microcirculatory dysfunction and the pathogenesis
of septic shock. Virulence. 2014;5(1):73–9. DOI: 10.4161/viru.26482.
9. Papadogeorgou P., Boutsikou T., Boutsikou M. et al. A global assessment of coagulation profile and a novel insight into ADAMTS‑13
implication in neonatal sepsis. Biology (Basel). 2023;12(10):1281.
DOI: 10.3390/biology12101281.
10. Levy J.H., Szlam F., Tanaka K.A., Sniecienski R.M. Fibrinogen and
hemostasis: a primary hemostatic target for the management of
acquired bleeding. Anesth Analg. 2012;114(2):261–74. DOI: 10.1213/
ANE.0b013e31822e1853.
11. Scully M., Levi M. How we manage haemostasis during sepsis. Br J
Haematol. 2019;185(2):209–18. DOI: 10.1111/bjh.15821.
12. Crochemore T., Scarlatescu E., Görlinger K. et al. Fibrinogen contribution to clot strength in patients with sepsis and hematologic malignancies and thrombocytopenia-a prospective, singlecenter, analytical, cross-sectional study. Res Pract Thromb Haemost.
2024;8(2):102362. DOI: 10.1016/j.rpth.2024.102362.
13. Lyanguzov A.V., Luchinin A.S., Sergunina O.Yu. et al. Clinical significance of screening coagulation tests in blood cancer patients
with sepsis. Tromboz, gemostaz i reologiya. 2024;(1):71–8. (In Russ.).
DOI: 10.25555/THR.2024.1.1088.
14. Meziani F., Iba T., Levy J.H., Helms J. Sepsis-induced coagulopathy: a matter of timeline. Intensive Care Med. 2024;50(8):1404–5.
DOI: 10.1007/s00134‑024‑07507‑3.
15. Collins P.W., Macchiavello L.I., Lewis S.J. et al. Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br J Haematol. 2006;135(2):220–7. DOI: 10.1111/j.1
365‑2141.2006.06281.x.
16. Spero J.A., Lewis J.H., Hasiba U. Disseminated intravascular coagulation. Findings in 346 patients. Thromb Haemost. 1980;43(1):28–33.
17. Li W.J., Sha M., Ma W. et al. Efficacy evaluation of D-dimer and
modified criteria in overt and nonovert disseminated intravascular coagulation diagnosis. Int J Lab Hematol. 2016;38(2):151–9.
DOI: 10.1111/ijlh.12467.
18. Omiya K., Sato H., SatoT. et al. Albumin and fibrinogen kinetics in
sepsis: a prospective observational study. Crit Care. 2021;25(1):436.
DOI: 10.1186/s13054‑021‑03860‑7.
19. Iba T., Levy J.H., Raj A., WarkentinT.E.Advance in the management
of sepsis-induced coagulopathy and disseminated intravascular
coagulation. J Clin Med. 2019;8(5):728. DOI: 10.3390/jcm8050728.
20. Dolmatova E.V., Wang K., Mandavilli R., Griendling K.K. The effects of sepsis on endothelium and clinical implications. Cardiovasc Res. 2021;117(1):60–73. DOI: 10.1093/cvr/cvaa070.
21. Bernardo A., Ball C., Nolasco L. et al. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support
leukocyte tethering and rolling under high shear stress. J Thromb
Haemost. 2005;3(3):562–70. DOI: 10.1111/j.1538‑7836.2005.01122.x.
22. Braun L.J., Stegmeyer R.I., Schäfer K. et al. Platelets docking to
VWF prevent leaks during leukocyte extravasation by stimulating
Tie‑2. Blood. 2020;136(5):627–39. DOI: 10.1182/blood.2019003442.
23. Bergmann S., Steinert M. From single cells to engineered
and explanted tissues: new perspectives in bacterial infection biology. Int Rev Cell Mol Biol. 2015;319:1–44. DOI: 10.1016/
bs.ircmb.2015.06.003.
24. Jagau H., Behrens I.K., LahmeK. et al. Von Willebrand factor mediates pneumococcal aggregation and adhesion in blood flow. Front
Microbiol. 2019;10:511. DOI: 10.3389/fmicb.2019.00511.
25. Steinert M., Ramming I., Bergmann S. Impact of von Willebrand
factor on bacterial pathogenesis. Front Med (Lausanne). 2020;7:543.
DOI: 10.3389/fmed.2020.00543.
26. Pappelbaum K.I., Gorzelanny C., Grässle S. et al. Ultralarge von Willebrand factor fibers mediate luminal Staphylococcus aureus adhesion to an intact endothelial cell layer under shear stress. Circulation. 2013;128(1):50–9. DOI: 10.1161/CIRCULATIONAHA.113.002008.
27. Nolasco J.G., Nolasco L.H., Da Q. et al. Complement component
C3 binds to the A3 domain of von Willebrand factor. TH Open.
2018;2(3):e338‑e345. DOI: 10.1055/s‑0038‑1672189.
28. Blasco M., Guillén-Olmos E., Diaz-Ricart M., Palomo M. Complement mediated endothelial damage in thrombotic microangiopathies. Front Med (Lausanne). 2022;9:811504. DOI: 10.3389/
fmed.2022.811504.
29. Avdonin P.P., Tsvetaeva N.V., Goncharov N.V. et al. Von Willebrand
factor in health and disease. Biochemistry (Moscow), Supplement
Series A: Membrane and cell biology. 2021;15(3):201–18. DOI: 10.1134/
S1990747821040036.
30. Sweeney J.M., Barouqa M., Krause G.J. et al. Low ADAMTS13 activity correlates with increased mortality in COVID‑19 patients. TH
Open. 2021;5(1): e89‑e103. DOI: 10.1055/s‑0041‑1723784.
31. Claus R.A., Bockmeyer C.L., Budde U. et al. Variations in the ratio
between von Willebrand factor and its cleaving protease during
systemic inflammation and association with severity and prognosis
of organ failure. Thromb Haemost. 2009;101(2):239–47. DOI: 10.1160/
th08‑03‑0161.
32. Lin J.J., Chan O.W., Hsiao H.J. et al. Decreased ADAMTS 13 activity is associated with disease severity and outcome in pediatric
severe sepsis. Medicine (Baltimore). 2016;95(16):e3374. DOI: 10.1097/
MD.0000000000003374.
33. Basaric D., Saracevic M., Bosnic V. et al. Factor VIII activity in
relation to the type of thrombosis and patient’s risk factors for
thrombosis, age, and comorbidity. Eurasian J Med. 2023;55(1):9–
13. DOI: 10.5152/eurasianjmed.2023.22072.
34. Lyanguzov A.V., Luchinin A.S., Ignatyev S.V. et al. Changes in
plasma concentration of von Willebrand factor and factor VIII
activity in hemoblastosis patients with infectious complications.
Medicinskij vestnik GVKG imeni N.N. Burdenko. 2024;1(15):66–72.
DOI: 10.53652/2782‑1730‑2024‑5‑1‑66‑72.
35. Levi M., de Jonge E., van der Poll T. Rationale for restoration of
physiological anticoagulant pathways in patients with sepsis and
disseminated intravascular coagulation. Crit Care Med. 2001;29(7
Suppl):S90–4. DOI: 10.1097/00003246‑200107001‑00028.
36. Levi M., Toh C.H., Thachil J., Watson H.G. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145(1):24–33. DOI: 10.1111/j.1365‑2141.2009.07600.x.
37. Iba T., Kidokoro A., Yagi Y. The role of the endothelium in changes
in procoagulant activity in sepsis. J Am Coll Surg. 1998;187(3):321–
9. DOI: 10.1016/s1072‑7515(98)00177‑x.
38. Warren B.L., Eid A., Singer P. et al.; KyberSept Trial Study Group.
Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA.
2001;286(15):1869–78. DOI: 10.1001/jama.286.15.1869.
39. Niederwanger C., Hell T., Hofer S. et al. Antithrombin deficiency
is associated with mortality and impaired organ function in septic pediatric patients: a retrospective study. Peer J. 2018;6:e5538.
DOI: 10.7717/peerj.5538.
40. Martí-Carvajal A.J., Solà I., Gluud C. et al. Human recombinant
protein C for severe sepsis and septic shock in adult and paediatric patients. Cochrane Database Syst Rev. 2012;12(12):CD004388.
DOI: 10.1002/14651858.CD004388.pub6.
41. Ikezoe T. Thrombomodulin/activated protein C system in septic
disseminated intravascular coagulation. J Intensive Care. 2015;3(1):1.
DOI: 10.1186/s40560‑014‑0050‑7.
42. Ling X.W., Lin K., Jiang X.Q. et al. International normalised ratio as
an independent predictor of mortality in limb necrotising fasciitis
with sepsis. Ann R Coll Surg Engl. 2021;103(1):35–40. DOI: 10.1308/
rcsann.2020.0189.
43. Zhang J., Du H.M., Cheng M.X. et al. Role of international normalized ratio in nonpulmonary sepsis screening: An observational
study. World J Clin Cases. 2021;9(25):7405–16. DOI: 10.12998/wjcc.
v9.i25.7405.
44. Schupp T., Weidner K., Rusnak J. et al. Diagnostic and prognostic significance of the prothrombin time/international normalized ratio in sepsis and septic shock. Clin Appl Thromb Hemost.
2022;28:10760296221137893. DOI: 10.1177/10760296221137893.
45. Collins P.W., Macchiavello L.I., Lewis S.J. et al. Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br J Haematol. 2006;135(2):220–7. DOI: 10.1111/j.1365‑2141.2006.06281.x.
46. Simmons J., Pittet J. F. The coagulopathy of acute sepsis. Curr Opin Anaesthesiol. 2015;28(2):227–36. DOI: 10.1097/
ACO.0000000000000163.
47. Muzaffar S.N., Baronia A.K., Azim A. et al. Thromboelastography for evaluation of coagulopathy in nonbleeding patients with
sepsis at intensive care unit admission. Indian J Crit Care Med.
2017;21(5):268–73. DOI: 10.4103/ijccm.IJCCM_72_17.
48. Boscolo A., Spiezia L., Campello E. et al. Whole-blood hypocoagulableprofile correlates with a greater risk of death within 28 days in patients with severe sepsis. Korean J Anesthesiol. 2020;73(3):224–31. DOI: 10.4097/kja.19396.
49. Tsantes A.G., Parastatidou S., Tsantes E.A. et al. Sepsis-induced
coagulopathy: an update on pathophysiology, biomarkers, and
current guidelines. Life (Basel). 2023;13(2):350. DOI: 10.3390/
life13020350.
50. Ostrowski S.R., Windeløv N.A., Ibsen M. et al. Consecutive thrombelastography clot strength profiles in patients with severe sepsis
and their association with 28‑day mortality: a prospective study.
J Crit Care. 2013;28(3):317.e1–11. DOI: 10.1016/j.jcrc.2012.09.003.
51. Zhou W., Zhou W., Bai J. et al. TEG in the monitoring of coagulation changes in patients with sepsis and the clinical significance.
Exp Ther Med. 2019;17(5):3373–82. DOI: 10.3892/etm.2019.7342.
52. Tuan T.A., Ha N.T.T., Xoay T.D. et al. Hypocoagulable tendency on
thromboelastometry associated with severity and anticoagulation timing in pediatric septic shock: a prospective observational
study. Front Pediatr. 2021;9:676565. DOI: 10.3389/fped.2021.676565.
53. Lyons P.G., Micek S.T., Hampton N., Kollef M.H. Sepsis-associated
coagulopathy severity predicts hospital mortality. Crit Care Med.
2018;46(5):736–42. DOI: 10.1097/CCM.0000000000002997.
54. Ren C., Li Y.X., Xia D.M. et al. Sepsis-associated coagulopathy predicts hospital mortality in critically ill patients with postoperative sepsis. Front Med (Lausanne). 2022;9:783234. DOI: 10.3389/
fmed.2022.783234.
55. Adamik B., GozdzikW., Jakubczyk D. et al. Coagulation abnormalities identified by thromboelastometry in patients with severe sepsis: the relationship to endotoxemia and mortality. Blood Coagul Fibrinolysis. 2017;28(2):163–70. DOI: 10.1097/MBC.0000000000000572.
56. Müller M.C., Meijers J.C., Vroom M.B., Juffermans N.P. Utility of
thromboelastography and/or thromboelastometry in adults with
sepsis: a systematic review. Crit Care. 2014;18(1):R30. DOI: 10.1186/
cc13721.
57. Rhodes A., Evans L.E., Alhazzani W. et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 2017;45(3):486–552. DOI: 10.1097/
CCM.0000000000002255.
58. Evans L., Rhodes A., Alhazzani W. et al. Surviving sepsis campaign:
international guidelines for management of sepsis and septic
shock 2021. Intensive Care Med. 2021;47(11):1181–247. DOI: 10.1007/
s00134‑021‑06506‑y.
59. Keith P.D., Wells A.H., Hodges J. et al. The therapeutic efficacy of
adjunct therapeutic plasma exchange for septic shock with multiple
organ failure: a single-center experience. Crit Care. 2020;24(1):518.
DOI: 10.1186/s13054‑020‑03241‑6.
60. David S., Bode C., Putensen C. et al.; EXCHANGE study group. Adjuvant therapeutic plasma exchange in septic shock. Intensive Care
Med. 2021;47(3):352–4. DOI: 10.1007/s00134‑020‑06339‑1.
61. Dietrich M., Hölle T., Lalev L.D. et al. Plasma transfusion in septic shock — a secondary analysis of a retrospective single-center
cohort. J Clin Med. 2022;11(15):4367. DOI: 10.3390/jcm11154367.
62. Qin X., Zhang W., Zhu X. et al. Early fresh frozen plasma transfusion: is it associated with improved outcomes of patientswith sepsis? Front Med (Lausanne). 2021;8:754859. DOI: 10.3389/
fmed.2021.754859.
63. Freedman M., Rock G. Analysis of the products of cryoprecipitation:
RiCoF is deficient in cryosupernatant plasma. Transfus Apher Sci.
2010;43(2):179–82. DOI: 10.1016/j.transci.2010.07.004.
64. Fung, Grossman M.K., Hillyer B.J. et al. Technical Manual of the
American Association of Blood Banks. 18th ed. 2014. 840 рp. Available at: https://ebooks.aabb.org/pdfreader/technical-manual‑18thedition. [Accessed: 28.04.2025].
65. Tseimakh E.A., Kundius S.A., BombizoV.A. et al. Comparative data
about cryosupernatant and fresh frozen plasma use in treatment
of disseminated intravascular coagulation in patients with generalized peritonitis. Anesteziologiya i reanimatologiya. 2014;(2):52–6. (In Russ.).
66. EIykomov V.A., Shoikhet Ya.N., Barkagan Z.S. et al. Comparison of
efficacy of cryosupernatant and freshly frozen plasma in patients
with acute lung abscess and gangrene. Pulmonologiya. 2002;(3):59–
64. (In Russ.).
67. Barkagan Z.S., Shoikhet Ya.N., EIykomov V.A. et al. Comparative
data on the use of cryosupernatant and fresh frozen plasma in
the treatment of protracted infectious-septic syndrome of disseminated intravascular coagulation. Terapevticheskii arkhiv.
1998;70(7):70–2. (In Russ.).
68. Galstyan G.M., Gaponova T.V., Sherstnev F.S. et al. Clinical guidelines for cryosupernatant transfusions. Gematologiya i transfuziologiya. 2020;65(3):351–9. (In Russ.). DOI: 10.35754/0234‑5730‑2020‑65‑3‑351‑359.
69. Kuznetsov S.I., AveryanovE.G., Davydova L.E. et al. Controversial
and indisputable in the recommendations for cryosupernatant
plasma transfusion. Transfuziologiya. 2021;22(2):179–87. (In Russ.).